MKMuhammed Cem Kockar

Muhammed Cem Kockar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muhammed Cem Kockar has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of BMI and Anticoagulant/Antiplatelet Therapy on the Severity of Gastrointestinal Bleeding

    by Melikşah Yüksel, Altuğ Şenol, Muhammet Cem Koçkar, Özgür Sirkeci, Naci Çil

    Background and Objectives: Obesity is a major global public health problem associated with numerous complications. Likewise, the use of antiplatelet and anticoagulant agents has increased with population aging and the growing burden of cardiovascular diseases. This study aimed to evaluate the effects of obesity and antiplatelet/anticoagulant therapy on the clinical presentation, bleeding severity, and short-term clinical outcomes of patients with gastrointestinal bleeding. Materials and Methods: A prospective cohort study was conducted in consecutive patients admitted with upper or lower gastrointestinal bleeding to a tertiary referral center between January 2024 and January 2025. Patients were categorized according to body mass index (BMI) and antithrombotic therapy status. Clinical characteristics, bleeding severity scores, treatment requirements, and short-term clinical outcomes were compared. Multivariable multinomial logistic regression analysis was performed to identify independent associations. Results: A total of 177 patients were included. Obese and overweight patients were significantly older than normal-weight patients (p = 0.001), whereas no significant differences were observed among BMI groups regarding the Glasgow–Blatchford score, pre-endoscopic Rockall score, transfusion requirements, endoscopic intervention, or short-term clinical outcomes. Patients receiving antiplatelet or anticoagulant therapy had significantly higher Charlson Comorbidity Index, bleeding severity scores, and packed red blood cell transfusion requirements than those receiving no antithrombotic therapy (all p < 0.01). However, after multivariable adjustment, these associations did not remain independent, and advanced age remained the only independent factor common to both treatment groups. Conclusions: Obesity was not independently associated with bleeding severity or short-term clinical outcomes in patients with gastrointestinal bleeding. Although antiplatelet and anticoagulant therapy were associated with more severe bleeding-related clinical findings, these associations were not independent after multivariable adjustment.

  • Open Access

    Dose‐dependent effects of kefir on colitis induced by trinitrobenzene sulfonic acid in rats

    by Nurhayat Ozkan Sevencan, Mehmet Isler, Fatma Nilgun Kapucuoglu, Altug Senol, Burcak Kayhan, Sefa Kiztanir, Muhammed Cem Kockar

    Evidence suggests that gut microbiota dysbiosis plays a critical role in the initiation and promotion of inflammatory bowel disease (IBD). Kefir is a fermented dairy product including yeast and bacterial species. We aimed to investigate the effect of kefir on trinitrobenzene sulfonic acid (TNBS)‐induced colitis in rats using two different doses. Fifty‐four Wistar rats were divided into six groups. For 14 days, the normal control and colitis control groups were given tap water, kefir10 control, kefir10 colitis, and kefir30 control, and the kefir30 colitis groups were given phosphate‐buffered saline containing 10% or 30% kefir, respectively, instead of tap water. Colitis was induced by intracolonically administrating TNBS in the colitis control, kefir10 colitis, and kefir30 colitis groups. On the 14th day, the rats were sacrificed. The weights and lengths of the colons were measured and macroscopically evaluated, and the distal 10 cm segments were subjected to a histopathological examination. The incidence of bloody stool and diarrhea in the kefir10 colitis group was found to be less than the colitis control and kefir30 colitis groups. The colonic weight/length ratio in the kefir10 colitis group was lower than that in the colitis control and kefir30 colitis groups. We detected that the 10% kefir treatment reduced TNBS‐induced macroscopic colonic damage, while it was exacerbated by the 30% kefir treatment. No significant difference was observed between the colitis groups in terms of microscopic colonic damage scoring. These results indicate that kefir, with a careful dose selection, may be a useful agent in the treatment of IBD.